IPO registrations (S-1, F-1) · Registrants

Aceragen, Inc.

SEC CIK
861838 · filings on EDGAR ↗
Name on the registration
IDERA PHARMACEUTICALS, INC.
Former names
IDERA PHARMACEUTICALS, INC. (2005–2023); HYBRIDON INC (1996–2005)
Registration
Form S-1, first filed 1998-12-23, last 2013-05-01; 3 initial registrations, 6 amendments
Outcome
Final prospectus filed 2013-05-02; declared effective 2006-08-09
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
505 EAGLEVIEW BOULEVARD, SUITE 212, Exton, PA 19341
EIN
04-3072298
EDGAR entity type
operating
Insiders and CEO pay
Aceragen, Inc. on the corporate pages

Offering terms

Final price
$0.50 per share (424B4 filed 2013-05-02)
Shares sold
17,500,000
Gross proceeds
$8,750,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol IDRA
Lead underwriters
Piper Sandler

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 29

FiledFormWhat it isName as filedEDGAR
1998-12-23S-1S-1 (registration)HYBRIDON INC0000922423-98-001428 ↗
1999-07-07S-1/AS-1/A (amendment)HYBRIDON INC0000922423-99-000859 ↗
2000-02-15S-1/AS-1/A (amendment)HYBRIDON INC0000922423-00-000370 ↗
2000-12-29S-1/AS-1/A (amendment)HYBRIDON INC0000950135-00-005579 ↗
2001-02-05S-1/AS-1/A (amendment)HYBRIDON INC0000950135-01-000268 ↗
2006-08-09EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-06-001139 ↗
2006-08-14S-1S-1 (registration)IDERA PHARMACEUTICALS, INC.0000950135-06-005044 ↗
2006-10-19EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-06-001965 ↗
2007-01-16EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-07-000184 ↗
2007-02-08EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-07-000523 ↗
2007-05-08EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-07-001808 ↗
2007-08-31EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-07-003512 ↗
2010-09-03EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-10-002638 ↗
2011-12-21EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-11-003602 ↗
2013-01-17EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-000212 ↗
2013-02-08EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-000440 ↗
2013-03-11S-1S-1 (registration)IDERA PHARMACEUTICALS, INC.0001193125-13-100015 ↗
2013-04-23S-1/AS-1/A (amendment)IDERA PHARMACEUTICALS, INC.0001193125-13-166154 ↗
2013-05-01S-1/AS-1/A (amendment)IDERA PHARMACEUTICALS, INC.0001193125-13-190099 ↗
2013-05-01EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-001341 ↗
2013-05-02424B4424B4 (final prospectus)IDERA PHARMACEUTICALS, INC.0001193125-13-196487 ↗
2013-07-10EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-002045 ↗
2013-08-27EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-002521 ↗
2013-08-28424B4424B4 (final prospectus)IDERA PHARMACEUTICALS, INC.0001193125-13-350307 ↗
2013-09-18EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-002708 ↗
2013-09-30424B4424B4 (final prospectus)IDERA PHARMACEUTICALS, INC.0001193125-13-384811 ↗
2013-11-15424B4424B4 (final prospectus)IDERA PHARMACEUTICALS, INC.0001193125-13-443926 ↗
2013-12-06EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-13-003468 ↗
2014-05-22EFFECTEFFECT (declared effective)IDERA PHARMACEUTICALS, INC.9999999995-14-001575 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-05-01S-1/Aregistration statement--Nasdaq IDRA1primary document; cover names 1document ↗
2013-05-02424B4final prospectus$0.5017,500,000$8,750,000Nasdaq IDRA1primary document; price sentence, shares headline, proceeds computed, cover names 1document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Alison Taunton-RigbyDirector132006–2009
HARTLEY C KEITHDirector202006–2013person page Fuzzy
REARDON WILLIAM SDirector342006–2018
WYNGAARDEN JAMES BDirector262006–2011
ZAMECNIK PAUL CDirector; Other212006–2008
ZEIN YOUSSEF ELDirector; Director,TenPercentOwner; TenPercentOwner912006–2023
AGRAWAL SUDHIRDirector,OfficerCEO & CSO; CEO & President; CEO, President & CSO; Chairman, CEO & President; President of Research262006–2017
ANDERSEN ROBERT GOfficerCFO & VP Oper. and Planning52006–2007
14159 capital (GP), LLCTenPercentOwner212006–2008
Baker Biotech Capital (GP), LLCTenPercentOwner202006–2008
Baker Biotech Capital II (GP), LLCTenPercentOwner32006
Baker Biotech Capital III (GP), LLCTenPercentOwner242006–2008
Baker Biotech Capital III (Z) (GP), LLCTenPercentOwner32006
Baker Biotech Capital II (Z) (GP), LLCTenPercentOwner32006
Baker Bros. Capital (GP), LLCTenPercentOwner202006–2008
BAKER FELIXDirector; Director,TenPercentOwner; Other; TenPercentOwner1262006–2019
BAKER JULIANDirector; Director,TenPercentOwner; Other; TenPercentOwner1262006–2019
Sullivan Timothy MOfficerVP Development Programs142006–2014
Karr Robert WDirector; Director,OfficerPresident112006–2014
Bexon AliceOfficerV.P. Clinical Development52007–2009
MUELLER HANSDirector132007–2011
Arcudi III Louis JOfficerChief Financial Officer152007–2018
MacCoss MalcolmDirector112010–2014
Arbeit Robert D.OfficerVP Clinical Development72010–2013
Slater Eve ElizabethDirector82010–2015
Senator Investment Group LPTenPercentOwner72010–2012
Pillar Invest CorpDirector,TenPercentOwner; TenPercentOwner372011–2023
Pillar Pharmaceuticals I LPDirector,TenPercentOwner; TenPercentOwner172011–2020
Abdul-Wahab UmariDirector122012–2014
Pillar Pharmaceuticals II, L.P.Director,TenPercentOwner; TenPercentOwner172012–2020
Pillar Pharmaceuticals III, L.P.Director,TenPercentOwner; TenPercentOwner112013–2020
GERAGHTY JAMES ADirector292013–2022
Pillar Pharmaceuticals IV, L.P.Director,TenPercentOwner; TenPercentOwner92013–2020
BRENNER LOUIS MDOfficerChief Medical Officer32014
Goldberg Mark AlanDirector182014–2022
14159, L.P.Director; Director,TenPercentOwner332014–2019
667, L.P.Director; Director,TenPercentOwner332014–2019
Baker Bros. Advisors (GP) LLCDirector; Director,TenPercentOwner; TenPercentOwner352014–2019
BAKER BROS. ADVISORS LPDirector; Director,TenPercentOwner; TenPercentOwner352014–2019
Baker Brothers Life Sciences LPDirector; Director,TenPercentOwner332014–2019
Neu KelvinDirector12014
MILANO VINCENTDirector; Director,OfficerPresident and CEO; PRESIDENT AND CEO; President & CEO242014–2023
Wolf John Peter IIIOfficerGeneral Counsel22014
Fletcher Robert C.OfficerSr. VP, Bus. Dev. & Strategy122015–2020
Casey Mark JOfficerSenior VP and General Counsel; Senior VP & General Counsel62015–2018person page Fuzzy
Horobin JoannaOfficerChief Medical Officer; SVP and Chief Medical Officer82015–2019
GOWEN MAXINEDirector142016–2023
Pillar Pharmaceuticals V LPDirector,TenPercentOwner; TenPercentOwner42016–2020
YINGLING JONATHAN MICHAELOfficerChief Scientific Officer; SVP, Early Development; SVP of Early Development92017–2020
Lim Bryant DavidOfficerSVP and General Counsel; SVP AND GENERAL COUNSEL; SVP & General Counsel192018–2023
PIEN HOWARD HDirector122018–2020
Kirby John J.OfficerChief Financial Officer; CHIEF FINANCIAL OFFICER; VP of Finance; V.P. of Finance, PFO & PAO172018–2023
SCHAFER CAROLDirector142018–2022
Csimma CristinaDirector62019–2022
DOUGHERTY MICHAEL RDirector202019–2023
Tarka Elizabeth AnnOfficerChief Medical Officer; CHIEF MEDICAL OFFICER62019–2021
Pillar Partners Foundation, L.P.TenPercentOwner152019–2023
Pillar Pharmaceuticals 6, L.P.TenPercentOwner122019–2023
Umari AbudeTenPercentOwner152019–2023
SOLAND DANIEL BOfficerChief Operating Officer; CHIEF OPERATING OFFICER82021–2022
JORDAN ANDREW ROfficerChief Strategy Officer; CHIEF STRATEGY OFFICER52022–2023
Kraus Carl NOfficerChief Medical Officer; CHIEF MEDICAL OFFICER42022–2023
Salain DanielOfficerChief Operating Officer; CHIEF OPERATING OFFICER42022–2023
Taylor John ClaytonDirector,OfficerChief Executive Officer; CHIEF EXECUTIVE OFFICER42022–2023
WOOTEN RONALD JDirector32022–2023
NovaQuest Co-Investment Fund XV, L.P.Director,Other; DirectorOther32022–2023
NQ POF V GP, Ltd.Director,Other; DirectorOther32022–2023
Chopra AtulTenPercentOwner42023

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Plan sponsorIDERA PHARMACEUTICALS, INC.PAForm 5500 (employee benefit plans)EIN (EXACT)
SEC filerAceragen, Inc.SEC filers (EDGAR)CIK (EXACT)
Form 5500 plan sponsorIDERA PHARMACEUTICALS, INC.EIN (EXACT)
Person pageC Keith HartleyPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)
Person pageMark J CaseyPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), PA first:

More with this interest.

In other datasets, the same topic (Health) in PA:

Interests: Biological Products, (No Diagnostic Substances) · Health